MedTrace Logo

Dapagliflozin in Mangement of Pulmonary Hypertension Patients

NCT06612086 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-10-29

No results posted yet for this study

Summary

Effect of SGLT2 (Dapagliflozin)on prognosis of patient with pulmonary Hypertension and Effect on RV function By speckle tract echocardiography at Assiut University Hospital.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Dapagliflozin (Forxiga)

we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-25
Primary Completion
2025-09-10
Completion
2026-10-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612086 on ClinicalTrials.gov